Pharmaceuticals News and Research

RSS

Noven claims patent infringement over Vivelle-Dot, files lawsuit against Mylan

Noven Pharmaceuticals, Inc. announced today that it has filed a lawsuit in the U.S. District Court for the Southern District of New York against Mylan Technologies Inc. ("Mylan") claiming infringement of certain Noven patents (the "Patents") by Mylan.

23 Feb 2011

USPTO issues Notice of Allowance to Somaxon's Silenor patent application

Somaxon Pharmaceuticals, Inc., a specialty pharmaceutical company, today announced that it has received a Notice of Allowance from the United States Patent and Trademark Office for claims in U.S. patent application no. 11/781,165.

23 Feb 2011

$Prolonged use of osteoporosis drugs may increase risk of unusual fractures in women$

Prolonged use of osteoporosis drugs may increase risk of unusual fractures in women

Women who take commonly prescribed drugs for osteoporosis known as bisphosphonates for five years or more may be at higher risk of certain kinds of fractures of their thigh bone, a new study has found.

23 Feb 2011

Regeneron submits VEGF Trap-Eye BLA to FDA for treatment of wet AMD

Regeneron Pharmaceuticals, Inc. announced that the company submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for VEGF Trap-Eye for the treatment of the neovascular form of age-related macular degeneration (wet AMD). Under the Prescription Drug User Fee Act (PDUFA), the goal for a standard review time from submission to FDA action is ten months.

22 Feb 2011

Novartis FLUAD seasonal flu vaccine for older adults receives Health Canada approval

Health Canada has approved FLUAD, a Novartis seasonal flu vaccine for adults 65 years and older. Canadian seniors are the hardest hit of all age groups by seasonal influenza and account for 90 per cent of influenza deaths and 70 per cent of hospitalizations.

22 Feb 2011

TransPharma completes ViaDor-GLP1 agonist Phase 1b trial for treatment of type II diabetes

TransPharma Medical Ltd., a specialty pharmaceutical company focused on the development and commercialization of drug products utilizing a proprietary active transdermal drug delivery technology, announced today the successful completion of a Phase 1b trial of ViaDor-GLP1 agonist, which is being developed for the treatment of diabetes mellitus type II.

22 Feb 2011

Infinity commences IPI-926 Phase 2 trial in patients with pancreatic cancer

Infinity Pharmaceuticals, Inc. today announced the initiation of the randomized Phase 2 portion of the trial of IPI-926 in combination with gemcitabine in patients with previously untreated, metastatic, pancreatic cancer.

22 Feb 2011

Gilead Sciences signs definitive agreement to acquire Calistoga for $375 million

Gilead Sciences, Inc. and Calistoga Pharmaceuticals, Inc., a privately-held biotechnology company focused on the development of medicines to treat cancer and inflammatory diseases, today announced the signing of a definitive agreement pursuant to which Gilead will acquire Calistoga for $375 million.

22 Feb 2011

Health Canada approves Orexo's Abstral to treat chronic cancer pain

Orexo AB today announces that ProStrakan's partner, Paladin Labs Inc. has been informed by Health Canada, the Canadian Government Department with responsibility for public health, that it has approved Abstral.

22 Feb 2011

Forest Labs enters definitive merger agreement to acquire Clinical Data

Forest Laboratories, Inc. and Clinical Data, Inc. today announced that they have entered into a definitive merger agreement pursuant to which Forest will acquire Clinical Data, a specialty pharmaceutical company focused on the development of first-in-class and best-in-category therapeutics, for $30.00 per share in cash plus contingent consideration of up to $6.00 per share that may be paid upon achievement of certain commercial milestones related to Viibryd.

22 Feb 2011

MedTrust, Avantra collaborate to develop molecular diagnostic assay for cancer care

MedTrust Online and Avantra Biosciences announced today a novel collaboration to involve clinicians in the earliest stages of molecular diagnostic assay development for Avantra Biosciences' revolutionary QPDx multiplex immunoassay system.

22 Feb 2011

Johnson & Johnson completes cash tender for Crucell shares, declares offer unconditional

Johnson & Johnson and Crucell N.V. today announce that Johnson & Johnson has completed the tender offer for Crucell N.V. and has declared the offer unconditional.

22 Feb 2011

Tropical seaweed's antifungal chemical cues may have promising antimalarial properties for humans

A group of chemical compounds used by a species of tropical seaweed to ward off fungus attacks may have promising antimalarial properties for humans. The compounds are part of a unique chemical signaling system that seaweeds use to battle enemies - and that may provide a wealth of potential new pharmaceutical compounds.

22 Feb 2011

Pharming, Santarus begin RHUCIN Phase IIIb study in patients with Hereditary Angioedema

Specialty biopharmaceutical company Santarus, Inc. and biotech company Pharming Group NV (NYSE Euronext: PHARM) today announced that Pharming has begun an international, multicenter, randomized, placebo-controlled Phase IIIb clinical study evaluating the investigational drug RHUCIN for the treatment of acute attacks of angioedema in patients with Hereditary Angioedema.

22 Feb 2011

CIBER completes key IT projects for leading healthcare organizations

CIBER, today announced it has recently completed key IT projects for leading healthcare organizations to develop and implement solutions that have helped the clients reduce costs, improve speed to market and engage consumers.

22 Feb 2011

New research: Fluid retention may explain drugs' risk of strokes and heart attacks

New research shows that medications which have raised safety concerns over heart attack and stroke risks may not have gotten approval from the Food and Drug Administration if the cardiovascular effects of fluid retention had been better understood. Fluid retention may explain the increased risk of heart attacks and strokes of medications such as Vioxx, Bextra, and Avandia.

22 Feb 2011

Positive results from TMC435 phase 2b PILLAR study in treatment-naive patients with HCV

Medivir AB, the emerging research-based specialty pharmaceutical company focused on infectious diseases, announces today further positive results from the phase 2b PILLAR study of TMC435 in treatment-naive patients with hepatitis C virus genotype-1.

22 Feb 2011

Motorola announces new advanced data capture solution for healthcare

Motorola Solutions, Inc. today announced its newest advanced data capture solution for healthcare - the DS4208-HC corded imager.

21 Feb 2011

The AFA initiates 2011 College Tour to educate young men and women about infertility

The American Fertility Association (The AFA), a national family-building non-profit organization, is heading to college campuses around the country to educate young men and women about infertility - a disease affecting one out of 6 couples in the U.S. The 2011 College Tour Series kicks off on March 4th at the University of Colorado in Boulder.

21 Feb 2011

CARBOGEN AMCIS installs new stability chambers at Switzerland facility

Switzerland-based CARBOGEN AMCIS AG, a pharmaceutical process development and Active Pharmaceutical Ingredient (API) manufacturing company, has expanded its service portfolio and capacity for stability studies. In compliance with the latest International Conference on Harmonisation (ICH) guidelines, and in response to customer demand, the company has installed new stability chambers at the Hunzenschwil (Neuland), Switzerland operations and offers short-term, long-term, accelerated, intermediate, follow-up and customized tests.

21 Feb 2011

Pharmaceuticals News and Research

Noven claims patent infringement over Vivelle-Dot, files lawsuit against Mylan

USPTO issues Notice of Allowance to Somaxon's Silenor patent application

Prolonged use of osteoporosis drugs may increase risk of unusual fractures in women

Regeneron submits VEGF Trap-Eye BLA to FDA for treatment of wet AMD

Novartis FLUAD seasonal flu vaccine for older adults receives Health Canada approval

TransPharma completes ViaDor-GLP1 agonist Phase 1b trial for treatment of type II diabetes

Infinity commences IPI-926 Phase 2 trial in patients with pancreatic cancer

Gilead Sciences signs definitive agreement to acquire Calistoga for $375 million

Health Canada approves Orexo's Abstral to treat chronic cancer pain

Forest Labs enters definitive merger agreement to acquire Clinical Data

MedTrust, Avantra collaborate to develop molecular diagnostic assay for cancer care

Johnson & Johnson completes cash tender for Crucell shares, declares offer unconditional

Tropical seaweed's antifungal chemical cues may have promising antimalarial properties for humans

Pharming, Santarus begin RHUCIN Phase IIIb study in patients with Hereditary Angioedema

CIBER completes key IT projects for leading healthcare organizations

New research: Fluid retention may explain drugs' risk of strokes and heart attacks

Positive results from TMC435 phase 2b PILLAR study in treatment-naive patients with HCV

Motorola announces new advanced data capture solution for healthcare

The AFA initiates 2011 College Tour to educate young men and women about infertility

CARBOGEN AMCIS installs new stability chambers at Switzerland facility

Industry Focus - Biopharma eBook

Latest eBooks

A practical guide to lipid nanoparticle formulation and resizing

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Improving healthcare sustainability through carbon data

Managing vibration in IVF laboratories

A New Approach to Preventing Bladder Cancer Recurrence